Pembrolizumab (NCT05967182)

Name: Pembrolizumab trial for Cholangiocarcinoma (NCT05967182)
Uploaded: 2026-10-31T16:24:36.080Z
Duration: 1 min 9 s
Description: Pembrolizumab trial for Cholangiocarcinoma (NCT05967182). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05967182.

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma: a one-minute explainerNCT059671821 min

Pembrolizumab trial for Cholangiocarcinoma (NCT05967182). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with high-risk, resectable intrahepatic cholangiocarcinoma confined to the liver, bile duct or regional lymph nodes. Prior systemic treatment for this cancer is excluded.

The idea: give pembrolizumab with gemcitabine and cisplatin infusions around surgery. Pembrolizumab blocks PD-1 to support immune attacks; the chemotherapy disrupts DNA production or damages DNA. Researchers assess tumor response in removed tissue, recurrence after surgery and safety. This is a single-group study, without a randomized surgery-only comparison.

This phase 2 study plans 24 patients. Hop Tran Cao leads MD Anderson’s Houston site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.